A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
← catalyst calendarNCT07277413 · readout in 620 d
Sponsored by IDEAYA Biosciences (industry) · IDYA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
260estimated
Sites
17
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-04 | actual | When the study began enrolling |
| Primary completion | 2028-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- NSCLC Adenocarcinoma
- Gastroesophageal Cancer (GC)
- Gastric Adenocarcinoma
- Adenocarcinoma of Esophagus
- Squamous Cell Car. - Esophagus
- Urothelial Carcinoma (UC)
- Bladder Cancer
- Mesothelioma
- Pleural Mesothelioma
- Peritoneal Mesothelioma
- Non-Small Cell Lung Cancer NSCLC
- Pancreatic Cancer
- Biliary Tract Carcinoma
Interventions
- Drug: IDE892
- Drug: IDE397
Primary outcomes
what the primary-completion date above is the date OFIncidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)
measured 21 days following the first dose of IDE892 (each cycle is 21 days)
Incidence of AEs and SAEs (Parts 1, 2, 3, and 4)
measured From first dose until 28 days after last dose (each cycle is 21 days)
Objective response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts 2 and 4)
measured Approximately 2 years
Permalink · IDYA's whole pipeline · Catalyst calendar · Every registered study · What changed